0000950170-23-028727.txt : 20230616 0000950170-23-028727.hdr.sgml : 20230616 20230616200012 ACCESSION NUMBER: 0000950170-23-028727 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230614 FILED AS OF DATE: 20230616 DATE AS OF CHANGE: 20230616 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harwin Peter Evan CENTRAL INDEX KEY: 0001663607 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36483 FILM NUMBER: 231022966 MAIL ADDRESS: STREET 1: 2001 MARKET STREET STREET 2: SUITE 2500 CITY: PHILADELPHIA STATE: PA ZIP: 19103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viridian Therapeutics, Inc.\DE CENTRAL INDEX KEY: 0001590750 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 471187261 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 BUSINESS PHONE: 617.272.4600 MAIL ADDRESS: STREET 1: 203 CRESCENT STREET STREET 2: BLDG. 17, SUITE 102B CITY: WALTHAM STATE: MA ZIP: 02453 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: MIRAGEN THERAPEUTICS, INC. DATE OF NAME CHANGE: 20170213 FORMER COMPANY: FORMER CONFORMED NAME: SIGNAL GENETICS, INC. DATE OF NAME CHANGE: 20140710 4 1 ownership.xml 4 X0407 4 2023-06-14 0001590750 Viridian Therapeutics, Inc.\DE VRDN 0001663607 Harwin Peter Evan C/O VIRIDIAN THERAPEUTICS, INC. 221 CRESCENT STREET, SUITE 401 WALTHAM MA 02453 true false false false false Stock Option (Right to Buy) 27.67 2023-06-14 4 A false 20000 0 A 2023-06-14 Common Stock 20000 20000 I See Footnote The option vests in full upon the earlier to occur of (i) June 14, 2024 or (ii) the Issuer's 2024 annual meeting of stockholders, subject to Reporting Person's continued service on the Board. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Lara Meisner, Attorney-in-Fact for Peter Evan Harwin 2023-06-16